ホーム>>Signaling Pathways>> Others>>R162

R162

カタログ番号GC32750

R162 は、グルタミン酸デヒドロゲナーゼ 1 (GDH1/GLUD1) の強力な阻害剤であり、抗がん特性があります。

Products are for research use only. Not for human use. We do not sell to patients.

R162 化学構造

Cas No.: 64302-87-0

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$68.00
在庫あり
5mg
$81.00
在庫あり
10mg
$142.00
在庫あり
25mg
$239.00
在庫あり
50mg
$414.00
在庫あり
100mg
$704.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

R162 is a potent inhibitor of glutamate dehydrogenase 1 (GDH1), with anti-cancer properties.

Inhibition of GDH1 activity by R162 treatment results in decreased intracellular fumarate levels, attenuated GPx activity, increased ROS levels, and reduced cell proliferation in H1299 and MDA-MB231 cells, which can be significantly rescued by methyl-α-KG treatment as well as by antioxidant NAC. R162 inhibits cell proliferation and tumor growth potential of human cancer cells[1].

R162 (30 mg/kg/day, i.p.) does not result in a significant histopathological change between the vehicle-treated and R162-treated groups, nor alters complete blood counts, or hematopoietic properties in xenograft tumor mouse models. R162 (20 mg/kg/day) results in significantly decreased tumor growth and masses in mice compared with control mice and effectively inhibits GDH1 activity in resected tumors from xenograft nude mice[1].

[1]. Jin L, et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell. 2015 Feb 9;27(2):257-70.

レビュー

Review for R162

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for R162

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.